UC Davis Health Clinical Studies

Studying Doses of Experimental GSK2330672 for Pruritus (itch) in Patients With Primary Biliary Cholangitis (damaged bile ducts)

This study drug is intended for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC).

This study will test the efficacy, safety and tolerability of GSK2330672. This study drug is intended for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Patients will receive either placebo or one of the 4 dose regimens of GSK2330672. The dose regiments are 20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily. Subjects on GSK2330672 will also receive placebo tablets to maintain blinding.

Drug study, Phase 2
Any, age 18 to 80 years old
Loading